Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

since the commencement of the grant in July 2005.

Research and development expenses for the three months ended June 30, 2008 and 2007 were $9.2 million and $10.5 million, respectively. Research and development expenses for the six months ended June 30, 2008 and 2007 were $20.6 million and $20.5 million, respectively. The decrease of $1.3 million for the three month period was primarily attributable to a decrease in preclinical and clinical costs incurred in connection with the research and development activities of our oncology pipeline. Research and development expenses for the six month periods were generally consistent from period to period.

General and administrative expenses for the three months ended June 30, 2008 and 2007 were $2.3 million and $2.1 million, respectively. General and administrative expenses for the six months ended June 30, 2008 and 2007 were $4.4 million in each period. The increase of $0.2 million for the three month period was primarily attributable to an increase in legal and professional fees offset by a decrease in share-based compensation expense.

SGX reported a net loss for the three months ended June 30, 2008 of $7.2 million, or $0.35 per share. This compares with a net loss for the three months ended June 30, 2007 of $4.0 million, or $0.26 per share. For the six months ended June 30, 2008, the net loss was $3.5 million, or $0.17 per share. This compares with a net loss for the six months ended June 30, 2007 of $5.1 million, or $0.33 per share. The net loss for the six months ended June 30, 2008 is less than the net loss for the three months ended June 30, 2008 due to the Company's reporting net income in the first quarter of 2008 as a result of the $10.8 million of revenue earned in the first quarter that was attributable to the one-time recognition of the remaining portion of the upfront payment related to the Company's collaboration with Novartis.

About SGX Pharmaceuticals

SGX Pharmaceuticals, Inc
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 Earlier this year ... L. Sherley, director of the Adult Stem Cell Technology ... often overlooked and under appreciated unique property of adult ... Distributed Stem Cells: Misunderstood in the Past, Important for ... congress participants. He gave the address at the ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)...  Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... Trial Application (CTA) with the United Kingdom,s ... regulatory approval to initiate clinical trials for the continued ... Contingent on the Company receiving CTA regulatory approval, the ... assess the safety, tolerability and dose escalation of Anatabine ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Nfocus device development team.PALO ALTO, Calif., April 30 ... today the appointment of accomplished regulatory executive Robert O,Holla ... President of Regulatory Affairs. "Bob O,Holla brings an unmatched ... , having served 18 of his last 30 years ...
... April 30 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... of drugs for the treatment of human viral diseases, today ... 31, 2009. At March 31, 2009, Idenix,s cash, cash equivalents ... , , ...
... Resonant Medical, an innovator in 3D ultrasound image-guided ... Stephen Whisenhunt to the position of Vice President ... the Company,s growing global sales team and manage ... years of radiation oncology industry experience to the ...
Cached Biology Technology:Nfocus Neuromedical Appoints Robert O'Holla to Head Regulatory 2Idenix Pharmaceuticals Reports First Quarter Financial Results 2Idenix Pharmaceuticals Reports First Quarter Financial Results 3Idenix Pharmaceuticals Reports First Quarter Financial Results 4Idenix Pharmaceuticals Reports First Quarter Financial Results 5Idenix Pharmaceuticals Reports First Quarter Financial Results 6Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing 2
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... it." The saying could apply especially to the brain ... studies have shown that keeping the mind active, exercising ... dementia in Alzheimer,s disease. Now, a new ... Center for Neurologic Diseases in the BWH Department of ...
... 5.8 million Americans suffer from heart failure, a currently ... Medicine,s (TUSM) Center for Translational Medicine have discovered a ... the development of new drugs to treat and possibly ... failure are not very effective," explained lead investigator Walter ...
... A team of European scientists from the University Medical Center ... Cellular Stress Responses in Aging-Associated Diseases (CECAD) at the ... closer to understanding the root cause of age-related dementia. In ... age-related dementia is likely the result of a declining ability ...
Cached Biology News:Use it or lose it 2Temple researchers discover key to heart failure, new therapies on horizon 2Temple researchers discover key to heart failure, new therapies on horizon 3Age-related dementia may begin with neurons' inability to dispose of unwanted proteins 2
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,381-3) or ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Anti-YAP Polyclonal Antibody ... purified rabbit polyclonal antibody. Detects 70 ... in Western blotting and immunohistochemistry. ... proliferation Storage: ...
... Stain for Mass Spectrometry Applications ,In ... (MS) has emerged as a powerful protein ... 2-D gels is now an important intermediate ... leads ultimately to identification of specific proteins ...
Biology Products: